Rapport Therapeutics, Inc. — Form 10-Q
Filed August 5, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 18/100
What the filing says
Rapport updated its non-employee director compensation policy effective June 10, 2026. Outside Directors receive $40,000 annual board retainer plus committee fees (Audit Chair $20,000, Compensation Chair $15,000, etc.). Initial equity grant: 30,400 stock options vesting over 3 years; annual grants: 15,200 options vesting within 1 year. Maximum annual compensation capped at $750,000 ($1,000,000 in initial year). Policy includes expense reimbursement and full vesting acceleration on sale events.
Why this rating
Routine governance disclosure; standard board compensation structure. No material financial impact or business change; administrative policy update only.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.